Lower Baseline Lung Function Linked to Sarcoidosis Response
Patients with shorter disease duration and lower lung function saw greater improvements in treatment trials.
Updated on Oct. 8, 2026 in Asthma
Live Poll
Should medical trial results more directly influence standard treatment approaches for chronic conditions?
A post-hoc analysis presented at the September 2026 ERS Congress identified factors that predict how well patients with pulmonary sarcoidosis respond to therapy. This research helps clarify which individuals may experience the most significant gains in lung function after starting treatment.
Why it matters
Identifying these predictors helps clinicians better understand which patients are most likely to benefit from specific interventions. This finding aims to refine future clinical trial designs and improve personalized treatment planning for those living with the condition.
In a post-hoc analysis of 135 patients from the 2025 PREDMETH trial, researchers found that lower baseline forced vital capacity (FVC) and shorter disease duration correlated with greater FVC improvement at week 24. These findings provide preliminary insights into predicting treatment efficacy.
The players
ERS Congress
An annual international meeting hosted by the European Respiratory Society that serves as a forum for presenting the latest advances in lung health research.
The details
Researchers utilized univariate and multivariate linear regression to determine how baseline FVC influences therapy outcomes. Patients were stratified at the median baseline FVC of 77% predicted to observe changes in respiratory function after initial treatment with either methotrexate or prednisone. The analysis specifically tracked the likelihood of reaching a 5% or 10% improvement threshold in lung capacity over the 24-week study period.
Timeline
The PREDMETH trial was published in 2025.
The analysis was presented at the ERS Congress in Barcelona from September 5-9, 2026.
Health Landscape
This study builds on the 2025 PREDMETH trial, which established methotrexate as a noninferior alternative to prednisone for pulmonary sarcoidosis. It represents a shift toward identifying patient-specific predictors of response to optimize treatment protocols.
If you are managing pulmonary sarcoidosis, these findings underscore why baseline lung function and early treatment intervention are key topics to discuss with your doctor. These metrics are important benchmarks to track with your specialist during your care planning.
The takeaway
Patients with shorter disease duration and lower lung function may see more pronounced improvements following treatment. Ask your physician about the clinical markers that might influence your specific treatment response and long-term lung function goals.
Further reading
For more information on the management of chronic respiratory conditions, visit Asthma.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical trial results more directly influence standard treatment approaches for chronic conditions?
